Protagonist Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.72
Dividend & YieldN/A$ (N/A)
Beta 2.34
Market capitalization 369.48M
Operating cash flow -103.44M
ESG Scores unknown

Company description

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -19.1M 30.31M -26.74M -14.27M
Total Cashflows From Investing Activities 2.21M -53.71M -90.97M -15.86M
Net Borrowings 9.77M 9.77M -10.52M
Total Cash From Financing Activities 24.11M 46.04M 247.63M 129.92M
Change To Operating Activities 3.85M -2M 3.28M 10.21M
Issuance Of Stock 24.11M 36.27M 258.16M 130.11M
Net Income -38.92M -77.19M -66.15M -125.55M
Change In Cash -23.8M -49.23M 84.35M 6.07M
Effect Of Exchange Rate -177k -26k 175k -126k
Total Cash From Operating Activities -49.95M -41.53M -72.48M -107.86M
Depreciation 527k 2.52M 2.72M 2.77M
Change To Account Receivables -2.77M -2.17M 4.33M 860k
Other Cashflows From Financing Activities -14k -14k -14k
Change To Netincome 6.47M 6.99M 10.08M 18.1M
Capital Expenditures -486k -967k -471k -1.1M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 59.5M 65M 74.51M 126.01M
Income Before Tax -39.72M -77.88M -64.84M -125.55M
Net Income -38.92M -77.19M -66.15M -125.55M
Selling General Administrative 13.7M 15.75M 18.64M 27.2M
Gross Profit 30.93M 231k 28.63M 27.36M
Ebit -42.27M -80.52M -64.52M -125.84M
Operating Income -42.27M -80.52M -64.52M -125.84M
Interest Expense -169k -169k -598k
Income Tax Expense -799k -691k 1.3M
Total Revenue 30.93M 231k 28.63M 27.36M
Cost Of Revenue
Total Other Income ExpenseNet 2.55M 2.64M -329k 294k
Net Income From Continuing Ops -38.92M -77.19M -66.15M -125.55M
Net Income Applicable To Common Shares -38.92M -77.19M -66.15M -125.55M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 26.96M 74.95M 44.86M 47.67M
Total Stockholder Equity 112.52M 79.96M 279.61M 300.02M
Other Current Liabilities 9.88M 19.12M 17.29M 2.91M
Total Assets 139.47M 154.92M 324.47M 347.69M
Common Stock
Other Current Assets 10k 10k 10k
Retained Earnings -140.47M -217.66M -283.81M -409.36M
Treasury Stock -233k -221k 28k -299k
Cash 82.23M 33.01M 117.36M 123.67M
Total Current Liabilities 26.16M 35.41M 40.24M 44.02M
Other Stockholder Equity -233k -221k 28k -299k
Property, Plant, and Equipment 861k 7.72M 6.41M 6.73M
Total Current Assets 137.5M 145.31M 315.61M 340.74M
Net Tangible Assets 112.52M 79.96M 279.61M 300.02M
Net Receivables 6.51M 7.5M 3.82M 5.33M
Accounts Payable 5.71M 2.79M 3.08M 1.6M


Insider Transactions

Here are the insider transactions of stock shares related to Protagonist Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
LIU DAVID Y.Conversion of Exercise of derivative security at price 0.87 - 4.21 per share.D2022-11-16Officer100.48k
MOLINA ARTUROStock Award(Grant) at price 0.00 per share.D2022-11-15Officer21.25k
PATEL DINESH V. PH.DConversion of Exercise of derivative security at price 4.21 per share.D2022-08-23Chief Executive Officer20k
PATEL DINESH V. PH.DConversion of Exercise of derivative security at price 4.21 per share.D2022-05-04Chief Executive Officer15.74k
WADDILL WILLIAM DConversion of Exercise of derivative security at price 8.59 per share.D2022-05-03Director12k
PATEL DINESH V. PH.DConversion of Exercise of derivative security at price 4.21 per share.D2022-04-26Chief Executive Officer30k
GUPTA SUNEELConversion of Exercise of derivative security at price 7.38 per share.D2022-04-26Officer40k
ALI ASIFStock Award(Grant) at price 0.00 per share.D2022-04-18Chief Financial Officer13.75k
PATEL DINESH V. PH.DConversion of Exercise of derivative security at price 1.89 per share.D2022-04-14Chief Executive Officer34.09k
KALKOFEN DONALD AStock Award(Grant) at price 0.00 per share.D2022-02-15Chief Financial Officer7.5k
PATEL DINESH V. PH.DStock Award(Grant) at price 0.00 per share.D2022-02-15Chief Executive Officer31.25k
LIU DAVID Y.Stock Award(Grant) at price 0.00 per share.D2022-02-15Officer10k
GUPTA SUNEELStock Award(Grant) at price 0.00 per share.D2022-02-15Officer12.5k
PATEL DINESH V. PH.DSale at price 32.14 per share.D2021-12-21Chief Executive Officer15k
PATEL DINESH V. PH.DConversion of Exercise of derivative security at price 4.21 per share.D2021-09-21Chief Executive Officer40k
LIU DAVID Y.Sale at price 47.56 per share.D2021-08-17Officer14.78k
LIU DAVID Y.Conversion of Exercise of derivative security at price 0.87 per share.D2021-08-17Officer10k
KALKOFEN DONALD AStock Award(Grant) at price 0.00 per share.D2021-02-26Chief Financial Officer7.5k
SAKS SAMUEL RStock Award(Grant) at price 0.00 per share.D2021-02-26Officer12k
PATEL DINESH V. PH.DStock Award(Grant) at price 0.00 per share.D2021-02-26Chief Executive Officer25k
LIU DAVID Y.Stock Award(Grant) at price 0.00 per share.D2021-02-26Officer10k
GUPTA SUNEELStock Award(Grant) at price 0.00 per share.D2021-02-26Officer12k
NOONBERG SARAH BStock Award(Grant) at price 24.59 - 25.09 per share.D2021-02-11Director8.4k
NOONBERG SARAH BSale at price 25.09 - 26.04 per share.D2021-02-11Director8.4k
NOONBERG SARAH BConversion of Exercise of derivative security at price 24.59 per share.D2021-02-10Director4.7k
PATEL DINESH V. PH.DSale at price 24.60 per share.D2021-01-19Chief Executive Officer24.85k
PATEL DINESH V. PH.DConversion of Exercise of derivative security at price 4.21 per share.D2021-01-19Chief Executive Officer13k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Protagonist Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Protagonist Therapeutics Inc

Here is the result of two systematic investment strategies applied to Protagonist Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Protagonist Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Protagonist Therapeutics Inc:

Protagonist Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 47.02% on the backtest period.

Performance at glance

Performance

47.02 %

Latent gain

1052.83 $

Invested capital

2238.92 $

Annualized return

11.36 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Protagonist Therapeutics Inc

This is the result of two momentum investment strategies applied to Protagonist Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Protagonist Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Protagonist Therapeutics Inc:

Protagonist Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 51.75% of return on Protagonist Therapeutics Inc. That represents 2963.41$ of latent gain with 5726.81$ of employed capital.
  • The second momentum investment strategy would give 87.96% of return on Protagonist Therapeutics Inc. That represents 3072.07$ of latent gain with 3492.62$ of employed capital.
Performance at glance (1Q Momentum)

Performance

51.75 %

Latent gain

2963.41 $

Invested capital

5726.81 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

87.96 %

Latent gain

3072.07 $

Invested capital

3492.62 $

Annualized return

24.03 %

Momentum equity curve on Protagonist Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Protagonist Therapeutics Inc:

Protagonist Therapeutics Inc momentum equity

Note: the dividends potentially given by Protagonist Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Protagonist Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Protagonist Therapeutics Inc since the beginning:

Protagonist Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Protagonist Therapeutics Inc

Buy the dip entry openings on Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

The performance achieved by the robo-advisor on Protagonist Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Protagonist Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Protagonist Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Protagonist Therapeutics Inc

The following chart shows the result of the investment strategy applied to Protagonist Therapeutics Inc:

Protagonist Therapeutics Inc

Note: the dividends potentially given by Protagonist Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Protagonist Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Protagonist Therapeutics Inc:

Protagonist Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Protagonist Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Protagonist Therapeutics Inc.

Equity curve comparison on Protagonist Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Protagonist Therapeutics Inc investment strategy comparison

Employed capital comparison on Protagonist Therapeutics Inc

Protagonist Therapeutics Inc investment comparison

Performance comparison on Protagonist Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 47.02% 1052.83$ 2238.92$ 11.36%
Momentum 1 quarter 51.75% 2963.41$ 5726.81$ 13.27%
Momentum 2 quarters 87.96% 3072.07$ 3492.62$ 24.03%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

11.36 %

Momentum 1Q

24.03 %

Momentum 2Q

24.03 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Protagonist Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Protagonist Therapeutics Inc

  • Most correlated stocks last 3 months

  • TOUCHSTAR PLC ORD 5P
  • Protagonist Therapeutics Inc
  • Salesforce Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • CHINA TOWER

  • Note: The algorithm computes the probability of correlation between Protagonist Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Protagonist Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Protagonist Therapeutics Inc
    Country United States
    City Newark
    Address 7707 Gateway Boulevard
    Phone 510 474 0170
    Website www.protagonist-inc.com
    FullTime employees 118
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker PTGX
    Market www.nasdaq.com

    Protagonist Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown